Coexistent in-stent restenosis, late incomplete stent apposition and mural thrombus in a zotarolimus-eluting stent

J Invasive Cardiol. 2008 Aug;20(8):423-5.


Drug-eluting stents (DES) have been demonstrated to dramatically reduce the rate of in-stent restenosis (ISR). However, some studies found an increased rate of late incomplete stent apposition (ISA) and late stent thrombosis (ST) in DES compared to traditional bare-metal stents (BMS). Endeavor stent, a new cobalt-alloy DES coated with phosphorylcholine and zotarolimus, has been reported to have a very favorable safety profile with few documented late-acquired ISA and late ST. In the present report, we described an interesting case with coexistent ISR, late ISA and mural thrombus in an Endeavor zotarolimus-eluting stent 8 months after primary percutaneous coronary intervention.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Angioplasty, Balloon, Coronary
  • Blood Vessel Prosthesis Implantation / adverse effects
  • Coronary Angiography
  • Coronary Restenosis / diagnosis
  • Coronary Restenosis / etiology*
  • Coronary Restenosis / therapy
  • Drug-Eluting Stents / adverse effects*
  • Heart Diseases / etiology
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Male
  • Myocardial Infarction / therapy
  • Prosthesis Failure*
  • Reoperation
  • Sirolimus / administration & dosage
  • Sirolimus / analogs & derivatives*
  • Thrombosis / etiology
  • Ultrasonography, Interventional


  • Immunosuppressive Agents
  • zotarolimus
  • Sirolimus